Curadev Pharma PVT. LTD. and Curadev Pharma Limited v. the University of Texas Southwestern Medical Center, Dr. Xiaochen Bai, and Dr. Xuewu Zhang

Court of Appeals of Texas·Decided August 21, 2025·No. 15-25-00004-CV·Published

Opinion

Affirmed and Majority and Concurring and Dissenting Opinions filed August 21, 2025.

In The

Fifteenth Court of Appeals

NO. 15-25-00004-CV

CURADEV PHARMA PVT. LTD. AND CURADEV PHARMA LIMITED, Appellants V.

THE UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER, DR. XIAOCHEN BAI, AND DR. XUEWU ZHANG, Appellees

On Appeal from the 101st District Court Dallas County, Texas Trial Court Cause No. DC-24-03875

MAJORITY OPINION

In this appeal, Appellants Curadev Pharma Pvt. Ltd and Curadev Pharma Limited (collectively, Curadev) challenge the trial court’s order granting the plea to the jurisdiction filed by Appellees the University of Texas Southwestern Medical Center (Southwestern), Dr. Xiaochen Bai, and Dr. Xuewu Zhang (collectively, Appellees). The underlying dispute arose after Appellees published research on potential treatment for cancer and other diseases. Curadev alleged that Appellees based their research on knowledge of Curadev’s proprietary information relating to a test compound provided to Southwestern by a third party. On appeal Curadev argues the trial court erred in (1) granting Appellees’ plea to the jurisdiction based on sovereign immunity; and (2) referring the plea to an Associate Judge.

Reviewing the jurisdictional allegations, taking them as true, and construing them in favor of Curadev, we conclude that Curadev’s amended petition does not present a claim for which sovereign immunity is waived and affirm the trial court’s order granting the pleas to the jurisdiction.

BACKGROUND 1

Curadev is a biotech company researching drug therapy directed toward ameliorating disease. One of Curadev’s drug programs involves the discovery of “small molecule agonists of human Stimulator of Interferon Genes (STING)” for the treatment of cancer. STING is “a critical protein in the generation of innate immune responses.” STING agonists are compounds that interact with and activate the STING protein. Curadev designed and developed several STING agonists. These agonists were allosteric human STING agonists that likely bound to a unique site in what is known as the “transmembrane region” of the STING protein. In 2019, Curadev licensed certain STING agonists to Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Co. Ltd. Neither Millennium Pharmaceuticals nor Takeda Pharmaceutical are parties to this litigation.

Defendants Bai and Zhang, employees of Southwestern, were also researching STING agonists and published a structure of STING, which included the transmembrane portion of the STING protein. In March 2019, Bai and Zhang

1 We review the facts as stated in Curadev’s live pleading.

2 “published a structure of full-length STING using cryo-electron microscopy (one of the methods that can be used to confirm whether a particular STING agonist is allosteric), which included the transmembrane portion of the STING protein.” Following Bai and Zhang’s publication, a Takeda subsidiary, Takeda California, Inc., entered into a Sponsored Collaboration Research Agreement (the Research Agreement) with Southwestern. Pursuant to the Research Agreement, Takeda provided Southwestern with one of Curadev’s STING agonist test compounds (Company Material).

In the Research Agreement, Southwestern described the project as studying “the interaction between the innate immunity adaptor protein STING and small molecule agonists that are developed by Takeda California, Inc.” Takeda agreed to supply Company Material to Southwestern for use in conducting a research program. Southwestern agreed not to distribute Company Material to any person or entity other than laboratory personnel at Southwestern. After completion of the research program or termination or expiration of the Research Agreement, Southwestern agreed to destroy all copies of Company Material.

The Research Agreement permitted Southwestern “to present or publish at their own choosing, methods and results of the Research Program under this Agreement.” It also contemplated that the parties may disclose confidential information to each other in connection with the work. The Research Agreement defined “Confidential Information” as “any scientific, technical, trade or business information possessed or obtained by, developed for or given to the recipient Party which is treated by the disclosing Party as confidential or proprietary.” The Research Agreement noted that the parties would use reasonable efforts to prevent disclosure of the other party’s confidential information for five years after receipt. The Research Agreement further provided that any inventions made jointly by

3 Southwestern and Takeda resided with Southwestern and Takeda. Southwestern granted Takeda an option to negotiate a license for any invention six months from the disclosure or discovery of the invention. After six months, Southwestern had the right to license any discovery without obligation to Takeda.

Curadev terminated its relationship with Takeda in April 2020. The Research Agreement between Takeda and Southwestern, by its terms, lasted until September 2, 2021. In October or November 2020, Curadev learned that Bai and Zhang “had generated data showing that Curadev’s test compound [Company Material] indeed bound to a unique allosteric transmembrane site on STING.” At that time, Appellees “were not aware that Curadev was the inventor of the test compound or of the chemical structure of the test compound or any of Curadev’s other compounds.”

Bai and Zhang subsequently published a paper on their research indicating potential uses for STING proteins in the treatment of disease. The paper, published in the magazine Nature, described how a Curadev compound known as C53 “bound a unique allosteric binding site to promote oligomerization and activation of STING.” Curadev alleged that C53 was “taken directly from Curadev’s library of compounds and is structurally related to the Curadev test compound provided to [Southwestern] by Takeda.”

Curadev sued Appellees alleging misappropriation of trade secrets, conversion, and an unlawful taking under Article I, Section 17 of the Texas Constitution. Curadev alleged that Appellees misappropriated Curadev’s trade secrets by continuing to conduct research using Company Material beyond the term of the Research Agreement between Takeda and Southwestern. Appellees answered and filed a plea to the jurisdiction, asserting immunity from suit under the doctrine of sovereign immunity. The trial court granted Appellees’ jurisdictional pleas and dismissed all claims asserted against them with prejudice. This appeal followed.

4 ANALYSIS

In Curadev’s first three issues, it argues that (1) a governmental entity’s disclosure and destruction of private trade secret property without just compensation constitutes an unconstitutional taking; (2) the trial court erred in granting Appellees’ plea to the jurisdiction and dismissing Curadev’s constitutional takings claim based on sovereign immunity; and (3) the trial court erred in granting Appellees’ plea to the jurisdiction and dismissing Curadev’s non-constitutional claims for misappropriation and conversion. In its fourth issue, Curadev asserts the trial court erred in referring the jurisdictional plea to an Associate Judge. We begin with the trial court’s ruling on the plea to the jurisdiction.

I. Standard of Review

Whether the trial court has jurisdiction is a question of law subject to de novo review. See Tex. Nat. Res. Conservation Comm’n v. IT-Davy, 74 S.W.3d 849, 855 (Tex. 2002).

Free access — add to your briefcase to read the full text and ask questions with AI

Curadev Pharma PVT. LTD. and Curadev Pharma Limited v. the University of Texas Southwestern Medical Center, Dr. Xiaochen Bai, and Dr. Xuewu Zhang, (Tex. Ct. App. 2025).

Curadev Pharma PVT. LTD. and Curadev Pharma Limited v. the University of Texas Southwestern Medical Center, Dr. Xiaochen Bai, and Dr. Xuewu Zhang (Curadev Pharma PVT. LTD. and Curadev Pharma Limited v. the University of Texas Southwestern Medical Center, Dr. Xiaochen Bai, and Dr. Xuewu Zhang) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

Arkansas Game & Fish Commission v. United States
133 S. Ct. 511 (Supreme Court, 2012)
SHEFFIELD DEVEL. CO. INC. v. City of Glenn Heights
140 S.W.3d 660 (Texas Supreme Court, 2004)
Texas Department of Parks & Wildlife v. Miranda
133 S.W.3d 217 (Texas Supreme Court, 2004)
State v. Holland
221 S.W.3d 639 (Texas Supreme Court, 2007)
Texas a & M University System v. Koseoglu
233 S.W.3d 835 (Texas Supreme Court, 2007)
Mission Consolidated Independent School District v. Garcia
253 S.W.3d 653 (Texas Supreme Court, 2008)
The City of El Paso v. Lilli M. Heinrich
284 S.W.3d 366 (Texas Supreme Court, 2009)
State v. Brownlow
319 S.W.3d 649 (Texas Supreme Court, 2010)
Franka v. Velasquez
332 S.W.3d 367 (Texas Supreme Court, 2011)
Texas Natural Resource Conservation Commission v. IT-Davy
74 S.W.3d 849 (Texas Supreme Court, 2002)
Tooke v. City of Mexia
197 S.W.3d 325 (Texas Supreme Court, 2006)
University of Texas Medical Branch v. York
871 S.W.2d 175 (Texas Supreme Court, 1994)
Texas Department of Transportation v. Able
35 S.W.3d 608 (Texas Supreme Court, 2000)
Seureau v. ExxonMobil Corp.
274 S.W.3d 206 (Court of Appeals of Texas, 2008)
Texas Department of Criminal Justice v. Miller
51 S.W.3d 583 (Texas Supreme Court, 2001)
Texas Bay Cherry Hill, L.P. v. City of Fort Worth
257 S.W.3d 379 (Court of Appeals of Texas, 2008)
Catalina Development, Inc. v. County of El Paso
121 S.W.3d 704 (Texas Supreme Court, 2003)
Wichita Falls State Hospital v. Taylor
106 S.W.3d 692 (Texas Supreme Court, 2003)